Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: corticosteroids

MCTD: Is It Just Letters?

Ruth Jessen Hickman, MD  |  December 4, 2024

At a Great Debate session, speakers discussed whether mixed connective tissue disease is a distinct disease entity in rheumatology.

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsOther Rheumatic Conditions Tagged with:ACR Convergence 2024connective tissue diseasemixed connective tissue disease (MCTD)

Top Research in Rheumatoid Arthritis Presented at ACR Convergence 2024

Jeffrey Curtis, MD, MS, MPH  |  December 3, 2024

Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 RA

Systemic Lupus Erythematosus: A Complex, Multi-Challenging Disease

Graciela S. Alarcón, MD, MPH, MACR  |  November 26, 2024

Reviewing the research presented at ACR Convergence 2024.

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsProfessional TopicsResearch ReviewsResearch RheumSystemic Lupus Erythematosus Tagged with:ACR Convergence 2024ACR Convergence 2024 SLE

Can Cultural Humility Conquer Systemic Inequity in Pediatric Rheumatology?

Glen Rodman  |  November 26, 2024

Doctors and patient advocates urged the rheumatology community to address the drastic inadequacies in care faced by marginalized people in a session held at ACR Convergence 2024.

Filed under:ACR ConvergenceLegislation & AdvocacyMeeting ReportsMeeting ReportsPatient PerspectivePediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2024Equitypatient advocacyPediatric

Collaborative Care Essential for Diagnosis & Care of Neurosarcoidosis

Ruth Jessen Hickman, MD  |  November 26, 2024

At a ACR Convergence 2024 session, experts discussed key characteristics, diagnostic challenges & treatment considerations for neurosarcoidosis.

Filed under:ACR ConvergenceConditionsMeeting ReportsMeeting ReportsOther Rheumatic Conditions Tagged with:ACR Convergence 2024Sarcoidosis

lupus nephritis, showing wire loop and hyaline thrombi, PAS stain, magnification 400x, photo under microscope

Lupus Nephritis Guideline Encourages Triple Therapy

Ruth Jessen Hickman, MD  |  November 24, 2024

Screening recommendations, triple therapy and more—here are insights into the upcoming ACR guideline for the care and treatment of patients with lupus nephritis.

Filed under:ACR ConvergenceClinical Criteria/GuidelinesConditionsGuidanceMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2024ACR Convergence 2024 SLEGuidelinesLupus nephritis

Diagnosing Skin Disease in Patients with Dark Skin

Thomas R. Collins  |  November 23, 2024

Many rheumatologists may not be trained to properly identify the signs of skin disease in patients with dark skin, but in this ACR Convergence session, experts provide practical guidance for diagnosis.

Filed under:ACR ConvergenceConditionsMeeting ReportsPsoriatic ArthritisSystemic Sclerosis Tagged with:ACR Convergence 2024

Lubricin/CD44/PP2A Pathway Offers New Therapeutic Targets for Patients with Gout

Ruth Jessen Hickman, MD  |  November 22, 2024

Dr. Khaled Elsaid discussed synovial macrophages/monocytes and monosodium urate crystal interactions at a session during ACR Convergence, exploring potential new gout pharmacology targets via the lubricin/CD44/protein phosphatase 2A (PP2A) pathway.

Filed under:ACR ConvergenceAmerican College of RheumatologyConditionsGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence 2024ACR Convergence 2024 goutGout

Rheumatic Manifestations of Diabetes (Mimics, Common Culprits & More)

Michael J. Cammarata, MD  |  November 11, 2024

Understanding the intersection of diabetes mellitus & rheumatic diseases, including lesser known rheumatic entities of diabetes, such as diabetic cheiroarthropathy, scleredema & diabetic myonecrosis, is crucial for accurate diagnosis.

Filed under:ConditionsOther Rheumatic Conditions Tagged with:diabetesEditor's Pick

Type I IFNs in Cutaneous Lupus & Dermatomyositis

Katie Robinson  |  October 14, 2024

Type I interferons (IFNs) play an important role in the immunopathogenesis of cutaneous lupus erythematosus and dermatomyositis skin inflammation, which could potentially be treated with IFN-targeted therapies.

Filed under:ConditionsMyositis Tagged with:Immunologytype I interferon

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 44
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences